Dynamic Technology Lab Private Ltd increased its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 221.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,073 shares of the biotechnology company’s stock after buying an additional 4,874 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in United Therapeutics Corporation were worth $828,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of UTHR. Capstone Asset Management Co. increased its holdings in United Therapeutics Corporation by 5.7% during the second quarter. Capstone Asset Management Co. now owns 6,047 shares of the biotechnology company’s stock worth $784,000 after buying an additional 324 shares during the last quarter. Mn Services Vermogensbeheer B.V. increased its holdings in United Therapeutics Corporation by 547.1% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 7,299 shares of the biotechnology company’s stock worth $947,000 after buying an additional 6,171 shares during the last quarter. LS Investment Advisors LLC increased its holdings in United Therapeutics Corporation by 15.8% during the second quarter. LS Investment Advisors LLC now owns 4,627 shares of the biotechnology company’s stock worth $600,000 after buying an additional 632 shares during the last quarter. State Treasurer State of Michigan increased its holdings in United Therapeutics Corporation by 1.6% during the second quarter. State Treasurer State of Michigan now owns 18,600 shares of the biotechnology company’s stock worth $2,413,000 after buying an additional 300 shares during the last quarter. Finally, US Bancorp DE increased its holdings in United Therapeutics Corporation by 3.2% during the second quarter. US Bancorp DE now owns 4,175 shares of the biotechnology company’s stock worth $541,000 after buying an additional 128 shares during the last quarter.

United Therapeutics Corporation (NASDAQ UTHR) opened at $125.41 on Thursday. The firm has a market cap of $5,419.10, a PE ratio of 11.06 and a beta of 1.38. United Therapeutics Corporation has a 1 year low of $112.01 and a 1 year high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, topping analysts’ consensus estimates of $4.01 by $2.26. The firm had revenue of $445.50 million during the quarter, compared to analyst estimates of $426.43 million. United Therapeutics Corporation had a net margin of 30.50% and a return on equity of 26.24%. The company’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter last year, the business earned $4.23 earnings per share. equities analysts expect that United Therapeutics Corporation will post 12.29 earnings per share for the current fiscal year.

In other news, Director Christopher Causey sold 580 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $134.48, for a total value of $77,998.40. Following the completion of the transaction, the director now directly owns 3,295 shares in the company, valued at $443,111.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,274 shares of the firm’s stock in a transaction that occurred on Thursday, September 21st. The shares were sold at an average price of $116.07, for a total transaction of $147,873.18. Following the completion of the transaction, the chief executive officer now owns 2,343 shares of the company’s stock, valued at $271,952.01. The disclosure for this sale can be found here. Insiders have sold 22,641 shares of company stock valued at $2,765,186 in the last quarter. Company insiders own 7.80% of the company’s stock.

UTHR has been the subject of a number of research analyst reports. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of United Therapeutics Corporation in a report on Friday, September 8th. BidaskClub downgraded shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Monday, July 31st. ValuEngine upgraded shares of United Therapeutics Corporation from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Zacks Investment Research upgraded shares of United Therapeutics Corporation from a “strong sell” rating to a “hold” rating in a report on Monday, October 9th. Finally, HC Wainwright restated a “hold” rating and set a $95.00 price objective on shares of United Therapeutics Corporation in a report on Thursday, October 26th. Five analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $132.82.

WARNING: This piece of content was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/23/united-therapeutics-corporation-uthr-shares-bought-by-dynamic-technology-lab-private-ltd.html.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.